The open-source nature of Llama 3 allows developers outside of Meta to customise the model to their needs.
By Vibhuti PathakApr 20, 2024
Meta has announced the launch of an enhanced AI assistant built on updated versions of its open-source Llama large language model, offering improved performance and intelligence.
According to a blog post from Meta, the latest Llama 3 models have led to a smarter and faster Meta AI. Co-founder and CEO Mark Zuckerberg expressed confidence in the new AI assistant, stating, "We believe Meta AI is now the most intelligent AI assistant that you can freely use."
— (@)
The open-source nature of Llama 3 allows developers outside of Meta to customise the model to their needs, and the company can then incorporate these improvements and insights in subsequent versions.
Meta is committed to reducing risks associated with AI and ensuring that the technology is developed and released responsibly. This includes implementing safeguards in the design and release of Llama models, as well as exercising caution when adding generative AI features to Facebook, Instagram, WhatsApp, and Messenger.
"We've made Meta AI easier to use across our apps," Zuckerberg explained in a video on Instagram, emphasising the seamless integration of AI within the search boxes on WhatsApp, Facebook, and Instagram Messenger.
AI models, including Meta's, can sometimes produce inaccurate or unexpected responses, a phenomenon known as "hallucinations." To counter this, Meta has been continually refining its AI technology to provide better, more reliable answers to prompts.
Meta is taking a steady approach to building its AI capabilities, which has initially placed the company behind in terms of consumer awareness and usage. However, the vast user base across its social media apps offers Meta a unique opportunity to quickly test and deploy AI-powered features to billions of users.
The company cited its efforts to refine AI responses, particularly on topics like politics and social issues, aiming to offer summaries of relevant points rather than one-sided views.
Meta's Llama 3 model has been tuned to better distinguish between innocuous and inappropriate prompts, preventing the AI from responding to potentially harmful queries.
To increase transparency, Meta will begin labeling AI-generated content such as video, audio, and images as "Made with AI" starting in May. Llama 3 is currently English-based, but Meta plans to release more advanced models that support multiple languages in the coming months.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.